医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Cell and Gene Therapy Industry Comes Together for Matica Bio’s New Global Event

2022年07月21日 PM10:00
このエントリーをはてなブックマークに追加


 

COLLEGE STATION, Texas

Matica Biotechnology, Inc. (Matica Bio), a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, hosted an inaugural event this week, Global Cell & Gene Day, with CHA Medical & Bio Group, providing a specialized venue for learning, innovation and networking for the advancing cell and gene therapy market.

Matica Bio has extensive experience in the clinical and commercial production of cell and gene therapies and recently opened its new 25,000-square-foot GMP facility in Texas dedicated to the production of viral vectors and cell-based products used in cell and gene therapies, vaccines, oncolytic therapies and other genetic medicines.

“Matica Bio understands the important role ongoing collaborations have in order to keep pace with this industry’s accelerated clinical development time frames, production complexities and increased demand,” said Matica Bio CEO Yun Jeong Song, M.D. “These include building opportunities for key industry interactions and discussions through events such as Global Cell & Gene Therapy Day, as well as establishing partnerships like ones we have in place with Sartorius and Texas A&M University’s Center for Innovation in Advanced Development and Manufacturing. It is essential that we are all working together as an industry for the future expansion of research, expertise, and successful product development.”

Over 400 attended Global Cell & Gene Day in Pangyo, South Korea. Speakers and topics in the program included a market overview from McKinsey & Co., a discussion on venture capital investment trends from Bain Capital and a summary of clinical trials and regulations from Parexel. Together with these industry experts, Matica Bio shared updates on CMC drug development. Presentations from this event can be made available by request.

Additional events from Matica Bio will be shared at: https://www.maticabio.com/news-upcoming-event.

About Matica Biotechnology, Inc.

Matica Biotechnology is a CDMO specialized for fully integrated cell and gene therapy manufacturing. The industry-leading experts at our state-of-the-art facility in College Station, Texas, deliver breakthrough therapies rapidly and safely through innovative manufacturing solutions. Advance your therapy from idea to patient with the experts at Matica Biotechnology. Visit www.maticabio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220721005239/en/

CONTACT

Lindsey Langemeier

SCORR Marketing

402-405-4269

lindsey@scorrmarketing.com

同じカテゴリーの記事 

  • Novaliq宣布VEVYE™ 0.1%(环孢素滴眼液)获得FDA批准,用于治疗干眼症的症状和体征
  • Parse Biosciences推出CRISPR Detect
  • パース・バイオサイエンシーズが新製品「CRISPR Detect」を発表
  • オルガノンとラテンアメリカ開発銀行(CAF)、女性の健康分野における持続可能な資金調達に向けた世界初の共同プロジェクトを開始
  • NTT Research and NCVC to Form Bio Digital Twin Center